|

mGnP Clinical Trials

1 actively recruiting trial across 1 location

No change since May 2026

Pipeline

Phase 3: 1

Top Sponsors

  • Immuneering Corporation1

Indications

  • PDAC1
  • Pancreatic Adenocarcinoma Metastatic1
  • Pancreatic Cancer Metastatic1
  • PDAC - Pancreatic Ductal Adenocarcinoma1
  • Pancreatic Ductal Adenocarcinoma (PDAC)1

Phoenix, Arizona1 trial

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

City of Hope

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.